Melatonin 1 mg

Natural health product licensed in Canada

Other names: Melatonin
Licence holder: WN Pharmaceuticals Ltd
NPN or DIN-HM: 80048886
Status: Active licence
Licence date: 3 March 2014
Revision date: 2 October 2025
Form: Comprimé
Route of administration: Sublinguale
Application type: Officinale

Oral dose analysis does not apply without an established exclusively oral route.

Composition

Medicinal ingredient and source	Per dosage unit, according to the source
N-acétyl-5-méthoxytryptamine	1 mg

Non-medicinal ingredients

Croscarmellose de sodium, Microcrystalline cellulose, Stéarate de magnésium, Saveur de menthe poivrée, Lactose

Recommended doses in Canada

Population	Age	Quantity per serving	Frequency
Adultes	Not specified	1 Comprimé	1 Tous les jours
Adultes	Not specified	3 Comprimé	1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Helps (to) increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule (e.g. shift-work and jet lag). Helps (to) prevent and/or reduce the effects of jet lag/minimize jet lag (e.g. daytime fatigue, sleep disturbance) (for people/if travelling by plane easterly across two or more time zones/flying east over two or more time zones). Helps (to) speed up/reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people who fall asleep slowly/with delayed sleep phase disorder. Helps (to) re-set the body's sleep-wake cycle (aspect of the circadian rhythm). May help alleviate abdominal pain associated with Irritable Bowel Syndrome (IBS). Helps reduce and/or prevent the daytime fatigue associated with jet lag. (Used as a) sleep aid (to help promote sleep).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.